Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aytu Biopharma Inc (NQ: AYTU )

3.174 -0.036 (-1.12%)
Streaming Delayed Price Updated: 9:43 AM EDT, May 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aytu Biopharma Inc

< Previous 1 2 3 Next >
Aytu BioPharma to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
ENGLEWOOD, CO / ACCESSWIRE / March 22, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that management... 
From Aytu BioPharma, Inc.
Via AccessWire
Aytu BioPharma to Participate in the 34th Annual Roth Conference
ENGLEWOOD, CO / ACCESSWIRE / March 8, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that Mark Oki,... 
From Aytu BioPharma, Inc.
Via AccessWire
Aytu BioPharma Announces Closing of $7.6 Million Registered Offering
ENGLEWOOD, CO / ACCESSWIRE / March 7, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the closing of... 
From Aytu BioPharma, Inc.
Via AccessWire
Aytu BioPharma Announces Pricing of $7.6 Million Registered Offering
ENGLEWOOD, CO / ACCESSWIRE / March 2, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the placement to... 
From Aytu BioPharma, Inc.
Via AccessWire
Aytu BioPharma Announces AR101 Granted Orphan Designation in Europe for the Treatment of Ehlers-Danlos Syndrome
ENGLEWOOD, CO / ACCESSWIRE / March 2, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that the European... 
From Aytu BioPharma, Inc.
Via AccessWire
Aytu BioPharma Announces Business and Pipeline Progress and Reports Second Quarter 2022 Financial Results
Quarterly Net Revenue Increased 53% Year-over-year to $23.1 Million PREVEnt Pivotal Study for AR101 in Vascular Ehlers-Danlos Syndrome On-track to Begin in Mid-2022 Initiation of Randomized,... 
From Aytu BioPharma, Inc.
Via AccessWire
Aytu BioScience, Inc. (NASDAQ:AYTU) Investor Alert: Investigation over Possible Violations of Securities Laws
San Diego, CA -- (SBWIRE) -- 01/31/2022 -- An investigation was announced on behalf of investors of Aytu BioScience, Inc. (NASDAQ:AYTU) shares over potential securities laws violations by Aytu... 
Via SBWire
Aytu BioPharma Completes $15 Million Debt Refinancing
ENGLEWOOD, CO / ACCESSWIRE / January 31, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that it has... 
From Aytu BioPharma, Inc.
Via AccessWire
Aytu BioPharma Appoints Mark Oki as Chief Financial Officer
ENGLEWOOD, CO / ACCESSWIRE / January 4, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today... 
From Aytu BioPharma, Inc.
Via AccessWire
Aytu BioPharma to Present at H.C. Wainwright BioConnect Conference
ENGLEWOOD, CO / ACCESSWIRE / January 3, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today... 
From Aytu BioPharma, Inc.
Via AccessWire
Investigation Announced for Investors in NASDAQ:AYTU Shares of Possible Violations of Securities Laws by Aytu BioScience, Inc
San Diego, CA -- (SBWIRE) -- 12/14/2021 -- Aytu BioScience, Inc is under investigation concerning potential securities laws violations in connection with certain financial statements. 
Via SBWire
Aytu BioPharma Announces FDA Clearance of Investigational New Drug (IND) Application for AR101/Enzastaurin in Vascular Ehlers-Danlos Syndrome
Pivotal clinical trial will begin in first half of 2022 ENGLEWOOD, CO / ACCESSWIRE / December 13, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel... 
From Aytu BioPharma, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Product Safety Regulatory
Aytu BioPharma Receives Orphan Drug Designation from FDA for AR101 for Treatment of Vascular Ehlers-Danlos Syndrome
ENGLEWOOD, CO / ACCESSWIRE / December 8, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products,... 
From Aytu BioPharma, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Product Safety Regulatory
Aytu BioScience, Inc. (NASDAQ: AYTU) Shareholder Notice: Investigation over Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 11/30/2021 -- Certain directors of Aytu BioScience, Inc are under investigation on over potential breaches of fiduciary dutie. 
Via SBWire
Aytu BioPharma Announces Issuance of First U.S. Patent Supporting Healight Ultraviolet-A Respiratory Catheter
ENGLEWOOD, CO / ACCESSWIRE / November 23, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products,... 
From Aytu BioPharma, Inc.
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
Aytu BioPharma Ranked Number 178 Fastest-Growing Company in North America on the 2021 Deloitte Technology Fast 50(TM)
ENGLEWOOD, CO / ACCESSWIRE / November 17, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products,... 
From Aytu BioPharma, Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Aytu BioPharma Reports First Quarter 2022 Financial Results
Quarterly net revenue increased 62% to $21.9 million Ended quarter with approximately $40.6 million in cash, cash equivalents and restricted cash Fully integrated and expanding RxConnect patient... 
From Aytu BioPharma, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Product Safety
Aytu BioPharma, Inc. (NASDAQ:AYTU) Investor Alert: Investigation over Possible Violations of Securities Laws
San Diego, CA -- (SBWIRE) -- 11/09/2021 -- An investigation was announced for investors of Aytu BioPharma, Inc. (NASDAQ:AYTU) shares over potential securities laws violations by Aytu BioPharma, Inc.... 
Via SBWire
Aytu BioPharma to Report First Quarter Fiscal 2022 Results and Provide Business Update on November 15, 2021
ENGLEWOOD, CO / ACCESSWIRE / November 8, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products,... 
From Aytu BioPharma, Inc.
Via AccessWire
CORRECTION: Aytu BioPharma to Present at Upcoming September Investor Conferences
(This release corrects the previous one that was issued on September 7, 2021 to reflect the time of the Cantor Presentation being changed to 2:40 pm EST) ENGLEWOOD, CO / ACCESSWIRE / September 30, 2021... 
From Aytu BioPharma, Inc.
Via AccessWire
Aytu BioPharma Reports Fourth Quarter and Full-Year Fiscal 2021 Financial Results
Quarterly net revenue increased 74% sequentially to $23.5M; 138% year-over-year to $65.6M Ended quarter with approximately $50M in cash, cash equivalents and restricted cash Planned pivotal study for... 
From Aytu BioPharma, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Product Safety
Aytu BioPharma to Report Fourth Quarter and Full Year Fiscal 2021 Results and Provide Business Update on September 27, 2021
ENGLEWOOD, CO / ACCESSWIRE / September 23, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products,... 
From Aytu BioPharma, Inc.
Via AccessWire
Aytu BioPharma Announces Formation of New Scientific Advisory Board to Support Development of AR101 for Vascular Ehlers-Danlos Syndrome
Chaired by Dr. Hal Dietz and joined initially by Dr. Xavier Jeunemaitre, Dr. Shaine Morris, Dr. Bart Loeys, and Dr. Peter Byers with additional advisors to be added ENGLEWOOD, CO / ACCESSWIRE /... 
From Aytu BioPharma, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
Aytu BioPharma to Present at Upcoming September Investor Conferences
ENGLEWOOD, CO / ACCESSWIRE / September 7, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products,... 
From Aytu BioPharma, Inc.
Via AccessWire
Aytu BioPharma Announces Publication of Data Demonstrating Ultraviolet-A Light Reduces Cellular Cytokine Release from Human Endotracheal Cells Infected with Coronavirus
ENGLEWOOD, CO / ACCESSWIRE / July 27, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products,... 
From Aytu BioPharma, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
Aytu BioPharma Announces Peer-Reviewed Publication of Clinical Results from Healight(TM) Pilot Study
Results Indicate That Endotracheal UVA Light Catheter Therapy is Associated with Significant Reduction in SARS-CoV-2 Viral Load and Improvement in Clinical Outcomes in Mechanically Ventilated COVID-19... 
From Aytu BioPharma, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
Aytu BioPharma to Present at Upcoming June Investor Conferences
ENGLEWOOD, CO / ACCESSWIRE / May 25, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products,... 
From Aytu BioPharma, Inc.
Via AccessWire
Aytu BioPharma Reports Fiscal Third Quarter 2021 Financial Results and Recent Business Highlights
- Closed merger with Neos Therapeutics creating a proforma combined $100 million revenue specialty pharmaceutical company - - Added late-stage pediatric onset rare disease asset, protein kinase C β... 
From Aytu BioPharma, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Product Safety
Aytu BioPharma Announces Publication of In Vitro Study Demonstrating That Ultraviolet-A Light Increases Mitochondrial Anti-Viral Signaling Protein Within Cells
ENGLEWOOD, CO / ACCESSWIRE / May 12, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products,... 
From Aytu BioPharma, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
Aytu BioPharma to Report Third Quarter Fiscal 2021 Results on May 17, 2021
ENGLEWOOD, CO / ACCESSWIRE / May 10, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products,... 
From Aytu BioPharma, Inc.
Via AccessWire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.